Kylie Prutisto-Chang

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

M. Lawrence, S. Digumarthy, A. Drilon, 2021, Clinical Cancer Research.

Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.

M. Mino‐Kenudson, L. Sequist, S. Ou, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

M. Lawrence, S. Digumarthy, C. Azzoli, 2020, Clinical Cancer Research.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

M. Lawrence, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, J. Engelman, 2018, Cancer discovery.